Details for Patent: 9,604,901
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,604,901 protect, and when does it expire?
Patent 9,604,901 protects REMODULIN, TYVASO DPI, TYVASO, and ORENITRAM, and is included in five NDAs.
This patent has fifteen patent family members in seven countries.
Summary for Patent: 9,604,901
Title: | Process to prepare treprostinil, the active ingredient in Remodulin.RTM. |
Abstract: | This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil. |
Inventor(s): | Batra; Hitesh (Herndon, VA), Tuladhar; Sudersan M. (Silver Spring, MD), Penmasta; Raju (Herndon, VA), Walsh; David A. (Palmyra, VA) |
Assignee: | United Therapeutics Corporation (Silver Spring, MD) |
Application Number: | 14/754,932 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,604,901 |
Patent Claim Types: see list of patent claims | Use; Formulation; Compound; |
Drugs Protected by US Patent 9,604,901
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-001 | May 21, 2002 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-002 | May 21, 2002 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-003 | May 21, 2002 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-004 | May 21, 2002 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
United Therap | REMODULIN | treprostinil | INJECTABLE;IV (INFUSION), SUBCUTANEOUS | 021272-005 | Jul 30, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-001 | May 23, 2022 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-002 | May 23, 2022 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,604,901
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 2710205 | See Plans and Pricing | |||
China | 101903324 | See Plans and Pricing | |||
China | 103274926 | See Plans and Pricing | |||
European Patent Office | 2252570 | See Plans and Pricing | |||
European Patent Office | 3287434 | See Plans and Pricing | |||
Spain | 2630407 | See Plans and Pricing | |||
Japan | 2011506599 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |